PolTREG S.A. Information

PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. Due to positive results of clinical trials of TREG method at the University Clinical Center in Gdansk, sharing this breakthrough therapy with as many patients as possible became the main focus of the company. During nearly two years of preparation prior to company’s establishment, business model, commercialization strategy and legal protection of invention were developed together with the University and research team. In July 2015 company was officially established with participation of University’s special purpose vehicle (SPV), R&D team – patent creators and implementation team, experienced in securing external funding and managing innovative projects. PolTREG is the only entity entitled to implementing the research findings in the area of T-regulatory lymphocytes and using their growth method for clinical use.